MWNA
RVMD icon

Marshall Wace North America’s Revolution Medicines RVMD Stock Holding History

Marshall Wace North America’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-51,903
Closed -$1.14M – 1434
2020
Q1 		$1.14M Buy
+51,903
New +$1.44M 0.01% 592

Other funds holding RVMD

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's RVMD Position: Q2 2020 in Review

Marshall Wace North America sold out of Revolution Medicines (RVMD) in Q2 2020, closing a stake of 51,903 shares — an estimated $1.14M sold.

Marshall Wace North America first reported a position in RVMD in Q1 2020 and held it in 1 quarter. The position peaked at $1.14M in Q1 2020. 77 funds tracked by Wall St. Rank hold RVMD as of Q2 2020.

  • Marshall Wace North America reported no remaining Revolution Medicines position as of Q2 2020 after selling out during the quarter.
  • Marshall Wace North America sold 51,903 Revolution Medicines shares in Q2 2020, an estimated $1.14M.
  • Marshall Wace North America first reported a position in Revolution Medicines in Q1 2020 and held it in 1 quarter.
  • Marshall Wace North America's Revolution Medicines position peaked at $1.14M in Q1 2020.
  • 77 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.